Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, Unicycive Therapeutics, Inc. reported revenue of $1M, down 29.0% year over year. Operating margin was -3077.6% and net margin -4525.0%, on a free-cash-flow margin of -2710.4% with capital expenditure at 1.8% of revenue. Every figure is computed directly from UNCY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $1M | -3077.6% | -4525.0% |
| FY2022 | $1M | -1898.2% | -1898.8% |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
How does UNCY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.